News | March 14, 2012

$45 Million Investment Accelerates Development of ViewRay's MRI-Guided Radiation Therapy System

$45 Million Investment Accelerates Development of ViewRay's MRI-Guided Radiation Therapy System

March 14, 2012 — ViewRay said it received $45 million in new financing to help speed development of its magnetic resonance imaging (MRI) image-guided radiation therapy (IGRT) system. The system provides a patented combination of simultaneous radiotherapy delivery and continuous MRI for the treatment of cancer.

ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance from the United States Food and Drug Administration (FDA) in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review.

The funding came from a round of series C venture capital financing. Institutional investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital (SVC) GmbH.

"Thanks to the ongoing commitment of our investors, ViewRay is in the process of preparing for market launch," said ViewRay president and CEO Gregory M. Ayers, M.D., Ph.D. "With our continued and substantial progress, our investors are even more enthusiastic about the potential of ViewRay and the promise of MRI-guided radiotherapy."

The first ViewRay research system is undergoing final installation at the Siteman Cancer Center at Barnes?Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri. Additional ViewRay research partners include the University of Wisconsin Carbone Cancer Center and the University of California, Los Angeles, Health System and Jonsson Comprehensive Cancer Center.

For more information: www.viewray.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...